COMPANY PROFILE

Minakem

Explore full profile

Building blocks, intermediates and Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry

Dunkerque, FranceFounded 2005Biotech & Life Sciences

Valuation $50–100M Last recorded · 2018

Revenue $10–50M Latest reported FY

Headcount 100–500 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Minakem

Minakem, a subsidiary of the Minafin Group, is a contract development and manufacturing organization (CDMO) that serves the pharmaceutical industry. The company specializes in the production of active pharmaceutical ingredients (APIs) and highly potent active pharmaceutical ingredients (HPAPIs), from laboratory-scale development to full industrial-scale manufacturing.

Its business model is centered around providing customized services to pharmaceutical companies, supporting them throughout their drug development lifecycle. This includes process development, analytical services, quality control, and regulatory support for filings with authorities like the FDA. Minakem operates several cGMP (current Good Manufacturing Practices) certified sites in Europe and the US, enabling it to serve a global client base ranging from small biotech startups to large pharmaceutical corporations. The company generates revenue by charging for its development services and for the commercial manufacturing of APIs.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2005
Headquarters: Dunkerque, France
Employees: 359
Open positions: 2
Dealroom signal: 63.7/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VC✓Equity / VC	Mar 2018	$16M	$64M	Minafin	—

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	Profit	Margin
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Minakem website traffic

Latest recorded traffic for Minakem is 2K monthly website visits, down 25.9% over the last three months. Minakem's team declined 3.8% over the past year.

Latest monthly visits2K 3-month web change-25.9% 1-year team growth-3.8%

Monthly website visitsMar 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Technicien(ne) de laboratoire CQ (HF) H/FDunkerque, France, Western Europe, Europe · Human Resources · Sep 8, 2026 2 Opérateurs de fabrication (H/F)Beuvry-la-Forêt, Hauts-de-France, France · Logistics · Aug 28, 2026

2 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NTNew American TherapeuticsA privately held, specialty pharmaceutical company that acquires, markets and develops products in select therapeutic areas	Parsippany-Troy Hills, United States	Operational	—	$53M	—
STSteel TherapeuticsFocused on increasing access to life-changing therapies with a track record of efficacy from compounding pharmacies	Iowa City, United States	Operational
CECellmAbsCellmabs is focused on researching and developing innovative biopharmaceuticals for the treatment of cancer	Óbidos, Portugal	Acquired
IBImmuneOnco BiopharmaDedicated to the development and commercialization of novel cancer immunotherapy products designed to reverse cancer cell-induced immune inhibition and to actively eradicate cancer cells	Huangpu, China	Operational
AUAutolusProgrammed T-cell immunotherapies for cancer and autoimmune diseases	London, United Kingdom	Operational
UPUppertonPharmaceutical CDMO for oral and nasal dosage forms	Nottingham, United Kingdom	Operational
CSCaris Life SciencesA profiling platform that identifies novel molecular targets to inform and enhance drug development and advanced diagnostics	Irving, United States	Operational
LTLeap TherapeuticsA biopharmaceutical company in the clinical stage, acquiring and advancing innovative therapeutics at the forefront of cancer research	Cambridge, United States	Operational